200 related articles for article (PubMed ID: 26368934)
1. Which and How Many Patients Should Be Included in Randomised Controlled Trials to Demonstrate the Efficacy of Biologics in Primary Sjögren's Syndrome?
Devauchelle-Pensec V; Gottenberg JE; Jousse-Joulin S; Berthelot JM; Perdriger A; Hachulla E; Hatron PY; Puechal X; Le Guern V; Sibilia J; Chiche L; Goeb V; Vittecoq O; Larroche C; Fauchais AL; Hayem G; Morel J; Zarnitsky C; Dubost JJ; Dieudé P; Pers JO; Cornec D; Seror R; Mariette X; Nowak E; Saraux A
PLoS One; 2015; 10(9):e0133907. PubMed ID: 26368934
[TBL] [Abstract][Full Text] [Related]
2. Development of the Sjögren's Syndrome Responder Index, a data-driven composite endpoint for assessing treatment efficacy.
Cornec D; Devauchelle-Pensec V; Mariette X; Jousse-Joulin S; Berthelot JM; Perdriger A; Puéchal X; Le Guern V; Sibilia J; Gottenberg JE; Chiche L; Hachulla E; Hatron PY; Goeb V; Hayem G; Morel J; Zarnitsky C; Dubost JJ; Seror R; Pers JO; Meiners PM; Vissink A; Bootsma H; Nowak E; Saraux A
Rheumatology (Oxford); 2015 Sep; 54(9):1699-708. PubMed ID: 25957440
[TBL] [Abstract][Full Text] [Related]
3. The efficacy and safety of total glucosides of peony in the treatment of primary Sjögren's syndrome: a multi-center, randomized, double-blinded, placebo-controlled clinical trial.
Liu X; Li X; Li X; Li Z; Zhao D; Liu S; Zhang M; Zhang F; Zhu P; Chen J; Wei W; Lin B; Zhou Y; Chen J; Pang Y; Zhang L; Sun X; Yu Z; Jia Y; Wang J; Sun W; Chiu F; Pang L; Wang G
Clin Rheumatol; 2019 Mar; 38(3):657-664. PubMed ID: 30280368
[TBL] [Abstract][Full Text] [Related]
4. Severe Health-Related Quality of Life Impairment in Active Primary Sjögren's Syndrome and Patient-Reported Outcomes: Data From a Large Therapeutic Trial.
Cornec D; Devauchelle-Pensec V; Mariette X; Jousse-Joulin S; Berthelot JM; Perdriger A; Puéchal X; Le Guern V; Sibilia J; Gottenberg JE; Chiche L; Hachulla E; Yves Hatron P; Goeb V; Hayem G; Morel J; Zarnitsky C; Dubost JJ; Saliou P; Pers JO; Seror R; Saraux A
Arthritis Care Res (Hoboken); 2017 Apr; 69(4):528-535. PubMed ID: 27390310
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of belimumab in primary Sjögren's syndrome: results of the BELISS open-label phase II study.
Mariette X; Seror R; Quartuccio L; Baron G; Salvin S; Fabris M; Desmoulins F; Nocturne G; Ravaud P; De Vita S
Ann Rheum Dis; 2015 Mar; 74(3):526-31. PubMed ID: 24347569
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of biological DMARDs modulating B cells in primary Sjögren's syndrome: Systematic review and meta-analysis.
Letaief H; Lukas C; Barnetche T; Gaujoux-Viala C; Combe B; Morel J
Joint Bone Spine; 2018 Jan; 85(1):15-22. PubMed ID: 28673789
[TBL] [Abstract][Full Text] [Related]
7. Epidemiology of cutaneous involvement in Sjögren syndrome: Data from three French pSS populations (TEARS, ASSESS, diapSS).
Villon C; Orgeolet L; Roguedas AM; Misery L; Gottenberg JE; Cornec D; Jousse-Joulin S; Seror R; Berthelot JM; Dieude P; Dubost JJ; Fauchais AL; Goeb V; Hachulla E; Hatron PY; Larroche C; Hayem G; Le Guern V; Perdriger A; Morel J; Vittecoq O; Mariette X; Devauchelle-Pensec V; Saraux A
Joint Bone Spine; 2021 Jul; 88(4):105162. PubMed ID: 33617999
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial.
Bowman SJ; Fox R; Dörner T; Mariette X; Papas A; Grader-Beck T; Fisher BA; Barcelos F; De Vita S; Schulze-Koops H; Moots RJ; Junge G; Woznicki JN; Sopala MA; Luo WL; Hueber W
Lancet; 2022 Jan; 399(10320):161-171. PubMed ID: 34861168
[TBL] [Abstract][Full Text] [Related]
9. Treatment of primary Sjögren syndrome with rituximab: a randomized trial.
Devauchelle-Pensec V; Mariette X; Jousse-Joulin S; Berthelot JM; Perdriger A; Puéchal X; Le Guern V; Sibilia J; Gottenberg JE; Chiche L; Hachulla E; Hatron PY; Goeb V; Hayem G; Morel J; Zarnitsky C; Dubost JJ; Pers JO; Nowak E; Saraux A
Ann Intern Med; 2014 Feb; 160(4):233-42. PubMed ID: 24727841
[TBL] [Abstract][Full Text] [Related]
10. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
11. Development and performance of the Clinical Trials ESSDAI (ClinTrialsESSDAI), consisting of frequently active clinical domains, in two randomised controlled trials in primary Sjögren's syndrome.
de Wolff L; Arends S; Pontarini E; Bombardieri M; Bowman SJ; Bootsma H
Clin Exp Rheumatol; 2021; 39 Suppl 133(6):100-106. PubMed ID: 34796851
[TBL] [Abstract][Full Text] [Related]
12. Brief Report: Ultrasonographic Assessment of Salivary Gland Response to Rituximab in Primary Sjögren's Syndrome.
Jousse-Joulin S; Devauchelle-Pensec V; Cornec D; Marhadour T; Bressollette L; Gestin S; Pers JO; Nowak E; Saraux A
Arthritis Rheumatol; 2015 Jun; 67(6):1623-8. PubMed ID: 25708147
[TBL] [Abstract][Full Text] [Related]
13. Effects of rituximab therapy on quality of life in patients with primary Sjögren's syndrome.
Devauchelle-Pensec V; Morvan J; Rat AC; Jousse-Joulin S; Pennec Y; Pers JO; Jamin C; Renaudineau Y; Quintin-Roué I; Cochener B; Youinou P; Saraux A
Clin Exp Rheumatol; 2011; 29(1):6-12. PubMed ID: 21345287
[TBL] [Abstract][Full Text] [Related]
14. Development and preliminary validation of the Sjögren's Tool for Assessing Response (STAR): a consensual composite score for assessing treatment effect in primary Sjögren's syndrome.
Seror R; Baron G; Camus M; Cornec D; Perrodeau E; Bowman SJ; Bombardieri M; Bootsma H; Gottenberg JE; Fisher B; Hueber W; van Roon JA; Devauchelle-Pensec V; Gergely P; Mariette X; Porcher R; ;
Ann Rheum Dis; 2022 Jul; 81(7):979-989. PubMed ID: 35393271
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of rituximab treatment in early primary Sjögren's syndrome: a prospective, multi-center, follow-up study.
Carubbi F; Cipriani P; Marrelli A; Benedetto P; Ruscitti P; Berardicurti O; Pantano I; Liakouli V; Alvaro S; Alunno A; Manzo A; Ciccia F; Gerli R; Triolo G; Giacomelli R
Arthritis Res Ther; 2013 Oct; 15(5):R172. PubMed ID: 24286296
[TBL] [Abstract][Full Text] [Related]
16. Seasonal effect on fatigue, pain and dryness in primary Sjögren's syndrome.
Duret PM; Meyer N; Saraux A; Devauchelle-Pensec V; Seror R; Le-Guern V; Larroche C; Perdriger A; Sibilia J; Guardiolle V; Mariette X; Gottenberg JE
Arthritis Res Ther; 2020 Feb; 22(1):39. PubMed ID: 32093783
[TBL] [Abstract][Full Text] [Related]
17. Eligibility for clinical trials in primary Sjögren's syndrome: lessons from the UK Primary Sjögren's Syndrome Registry.
Oni C; Mitchell S; James K; Ng WF; Griffiths B; Hindmarsh V; Price E; Pease CT; Emery P; Lanyon P; Jones A; Bombardieri M; Sutcliffe N; Pitzalis C; Hunter J; Gupta M; McLaren J; Cooper A; Regan M; Giles I; Isenberg D; Saravanan V; Coady D; Dasgupta B; McHugh N; Young-Min S; Moots R; Gendi N; Akil M; Barone F; Fisher B; Rauz S; Richards A; Bowman SJ;
Rheumatology (Oxford); 2016 Mar; 55(3):544-52. PubMed ID: 26510429
[TBL] [Abstract][Full Text] [Related]
18. A multi-center, open-label, randomized study to explore efficacy and safety of baricitinib in active primary Sjogren's syndrome patients.
Bai W; Yang F; Xu H; Wei W; Li H; Zhang L; Zhao Y; Shi X; Zhang Y; Zeng X; Leng X
Trials; 2023 Feb; 24(1):112. PubMed ID: 36793118
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of iguratimod on patients with primary Sjögren's syndrome: a randomized, placebo-controlled clinical trial.
Shao Q; Wang S; Jiang H; Liu L
Scand J Rheumatol; 2021 Mar; 50(2):143-152. PubMed ID: 33118847
[No Abstract] [Full Text] [Related]
20. Selection of study endpoints and patients for clinical trials in primary Sjögren's syndrome.
Arends S; de Wolff L; Deroo L; Verstappen GM; Vissink A; Kroese FGM; Elewaut D; Peene I; Bootsma H
Clin Exp Rheumatol; 2022 Dec; 40(12):2225-2232. PubMed ID: 36305355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
